Bridging the Gap Between In Vitro and In Vivo Drug Discovery
Translating early-stage drug discovery into clinical success is one of the biggest challenges in drug development. Ensuring that target engagement observed in in vitro assays holds true in vivo is critical for making informed decisions and improving translational research outcomes.
In this on-demand webinar, Jon Ellery, Director of Biology at Sitryx, shares how CETSA technology helped Sitryx assess target engagement and improve translational confidence in small molecule drug discovery.
Key Takeaways:
- How CETSA improves decision-making – Learn how CETSA helped Sitryx validate target engagement and optimize small molecule development.
- Bridging the in vitro–in vivo gap – See how CETSA provided crucial insights for translational pharmacology and preclinical drug development.
- Case study: CETSA in action – Follow a real-world drug discovery case study applying CETSA to a promising therapeutic candidate.
Watch the Webinar On-Demand
Access the recording now to gain valuable insights into CETSA technology and its role in strengthening preclinical drug development.
Meet the Expert Speaker
Jon Ellery
Director of Biology, Sitryx
Jon Ellery is an expert in analytical pharmacology, translational research, and early-stage drug development. With experience at Takeda, Cancer Research UK, and Sitryx, he specializes in optimizing small molecule drug discovery strategies to enhance clinical success.
